Tumor ablation is a treatment that destroys cancerous tumors without removing them. This is done using a probe that utilizes thermal energy to heat or cool tumorigenic tissue to cytotoxic levels. Techniques such as computed tomography (CT), ultrasound (US), and magnetic resonance imaging (MRI) are used to guide and position the needle probe into the tumor. Tumor ablative techniques are used in patients having few tumors which are small in size. Ablation is best used for tumors no larger than an inch. For slightly larger tumors, ablation could be used along with embolization. Moreover, surgery for tumor removal is not a feasible treatment option for certain patients often due to poor health or reduced immunity, or reduced organ function. For such cases, tumor ablation is the preferred form of treatment prescribed. Tumor ablation treatment is also highly useful in patients who are awaiting liver transplant.
Browse Market Research Report @ http://www.transparencymarketresearch.com/tumor-ablation-market.html
Rise in cancer incidence coupled with growing preference for minimally invasive treatment options is anticipated to drive the tumor ablation market during the forecast period. However, the size of tumor treatable with this technique remains a challenge. Utilization of combination therapies to ameliorate this challenge shall further propel the market during the forecast period. Technological advancements pertaining to ablation devices is also likely to boost growth of the tumor ablation devices market. High cost of certain tumor ablation techniques such as cryoablation is likely to restrain the market during the forecast period.
The tumor ablation market has been segmented based on type of modality, application, end-user, and region. In terms of type of modality, the market has been segmented into radiofrequency ablation, laser ablation, microwave ablation, and cryoablation. Radiofrequency ablation (RFA) is the percutaneous ablative modality most commonly used for tumor ablation in developed regions of the world. Hence, the radiofrequency ablation segment is anticipated to capture a significant share of the tumor ablation market during the forecast period. Cryoablation, although expensive, is a relatively painless procedure, which enables treatment of fragile patients who are not in a position to tolerate anesthesia. Based on application, the market has been segmented into liver cancer, lung cancer, breast cancer, prostate cancer, bone cancer, kidney cancer, and other cancers. The liver cancer segment is anticipated to account for significant share of the tumor ablation market in terms of revenue owing to its preference as a mode of treatment for liver cancer patients.
In terms of end-user, the market has been divided into hospitals, cancer specialty clinics, and ambulatory surgical centers. The patients going in for tumor ablation treatment typically do not require hospital stay. Hence, the ambulatory surgical centers and cancer specialty clinics segments are anticipated to witness higher growth during the forecast period.
Based on region, the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to Cancer Research UK, the incidence rate of liver cancer is projected to rise by 38% in the U.K. between 2014 and 2035. Moreover, through the last decade, liver cancer incidence rate has increased by more than half (53%) in the U.K. Hence, the tumor ablation market is anticipated to witness robust growth in the U.K. during the forecast period. In the U.S. too, liver cancer incidence has more than tripled since 1980. However, cancer incidence is higher in Asia Pacific and preference for minimally invasive surgeries is rising in the region. Therefore, the market in Asia Pacific is likely to expand at a high CAGR during the forecast period.
Fill the form to gain deeper insights on this market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18656
Major players operating in the market include Medtronic, Merit Medical Systems, Inc., AngioDynamics, Inc., AtriCure, Inc., BVM Medical Limited, St. Jude Medical, Inc., DFINE, Inc., Boston Scientific Corporation, Perseon Corporation, and NeuWave Medical, Inc.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453